Dasatinib (DAS), a multi-kinase inhibitor targeting Src and BCR-ABL families, is approved for Ph+ acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CML). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.